HEPZATO — Topline data
Late 2028
The trial's primary endpoint, hPFS, is anticipated to read out by the end of 2028, while results for OS, a secondary endpoint, is expected in 2029.Source filing
DCTH biotech catalysts & pipeline
DELCATH SYSTEMS INC · Data as of 2026-10-25
Upcoming catalysts
HEPZATO — Clinical data readout
Sep 2028–Apr 2029
OS expected in late 2028/early 2029.Source filing
HEPZATO — Clinical data readout
2030
OS expected in 2030.Source filing